Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques
- PMID: 14981511
- PMCID: PMC7095986
- DOI: 10.1038/nm1001
Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques
Abstract
The primary cause of severe acute respiratory syndrome (SARS) is a newly discovered coronavirus. Replication of this SARS coronavirus (SCV) occurs mainly in the lower respiratory tract, and causes diffuse alveolar damage. Lack of understanding of the pathogenesis of SARS has prevented the rational development of a therapy against this disease. Here we show extensive SCV antigen expression in type 1 pneumocytes of experimentally infected cynomolgus macaques (Macaca fascicularis) at 4 d postinfection (d.p.i.), indicating that this cell type is the primary target for SCV infection early in the disease, and explaining the subsequent pulmonary damage. We also show that prophylactic treatment of SCV-infected macaques with the antiviral agent pegylated interferon-alpha (IFN-alpha) significantly reduces viral replication and excretion, viral antigen expression by type 1 pneumocytes and pulmonary damage, compared with untreated macaques. Postexposure treatment with pegylated IFN-alpha yielded intermediate results. We therefore suggest that pegylated IFN-alpha protects type 1 pneumocytes from SCV infection, and should be considered a candidate drug for SARS therapy.
Conflict of interest statement
The authors declare no competing financial interests.
Figures
Similar articles
-
SARS treatment. Interferon shows promise in monkeys.Science. 2004 Feb 27;303(5662):1273-5. doi: 10.1126/science.303.5662.1273a. Science. 2004. PMID: 14988528 No abstract available.
-
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome.Lancet. 2003 Jul 26;362(9380):263-70. doi: 10.1016/S0140-6736(03)13967-0. Lancet. 2003. PMID: 12892955 Free PMC article.
-
Mouse-passaged severe acute respiratory syndrome-associated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice.Am J Pathol. 2008 Jun;172(6):1625-37. doi: 10.2353/ajpath.2008.071060. Epub 2008 May 8. Am J Pathol. 2008. PMID: 18467696 Free PMC article.
-
The aetiology of SARS: Koch's postulates fulfilled.Philos Trans R Soc Lond B Biol Sci. 2004 Jul 29;359(1447):1081-2. doi: 10.1098/rstb.2004.1489. Philos Trans R Soc Lond B Biol Sci. 2004. PMID: 15306393 Free PMC article. Review.
-
Recent patents on treatment of severe acute respiratory syndrome (SARS).Recent Pat Antiinfect Drug Discov. 2007 Jan;2(1):1-10. doi: 10.2174/157489107779561698. Recent Pat Antiinfect Drug Discov. 2007. PMID: 18221160 Review.
Cited by
-
Harnessing the power of IFN for therapeutic approaches to COVID-19.J Virol. 2024 May 14;98(5):e0120423. doi: 10.1128/jvi.01204-23. Epub 2024 Apr 23. J Virol. 2024. PMID: 38651899 Free PMC article. Review.
-
Pathogenesis and virulence of coronavirus disease: Comparative pathology of animal models for COVID-19.Virulence. 2024 Dec;15(1):2316438. doi: 10.1080/21505594.2024.2316438. Epub 2024 Feb 16. Virulence. 2024. PMID: 38362881 Free PMC article. Review.
-
SARS-CoV-2 immunity in animal models.Cell Mol Immunol. 2024 Feb;21(2):119-133. doi: 10.1038/s41423-023-01122-w. Epub 2024 Jan 18. Cell Mol Immunol. 2024. PMID: 38238440 Free PMC article. Review.
-
Interferon regulatory factor 3 mediates effective antiviral responses to human coronavirus 229E and OC43 infection.Front Immunol. 2023 May 1;14:930086. doi: 10.3389/fimmu.2023.930086. eCollection 2023. Front Immunol. 2023. PMID: 37197656 Free PMC article.
-
Recent advances in small-molecular therapeutics for COVID-19.Precis Clin Med. 2022 Sep 24;5(4):pbac024. doi: 10.1093/pcmedi/pbac024. eCollection 2022 Dec. Precis Clin Med. 2022. PMID: 36268466 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous